RB-101: Difference between revisions
CSV import |
CSV import |
||
| Line 27: | Line 27: | ||
{{stub}} | {{stub}} | ||
== RB-101 == | |||
<gallery> | |||
File:RB-1012DCSD.svg|RB-101 | |||
File:RB-1013DanJ.gif|RB-101 | |||
</gallery> | |||
Latest revision as of 01:44, 20 February 2025
RB-101 is a drug that acts as an enzyme inhibitor, specifically inhibiting the enzyme enkephalinase, which breaks down enkephalins, a type of endogenous opioid in the body. RB-101 is a prodrug which is converted into the active compound, RB-120, in the body. This drug has been researched for its potential use in the treatment of pain, depression, and addiction.
Mechanism of action[edit]
RB-101 works by inhibiting the enzyme enkephalinase, which is responsible for the degradation of enkephalins. Enkephalins are endogenous opioids, meaning they are opioids that are naturally produced by the body. By inhibiting the breakdown of these opioids, RB-101 increases their concentration in the body, leading to increased opioid activity.
Potential therapeutic uses[edit]
RB-101 has been researched for its potential use in several therapeutic areas. These include the treatment of pain, depression, and addiction.
Pain[edit]
RB-101 has been shown to have analgesic effects in animal models of pain. This is likely due to its ability to increase the concentration of enkephalins in the body, which have analgesic properties.
Depression[edit]
Research has suggested that RB-101 may have antidepressant effects. This is thought to be due to its ability to increase the concentration of enkephalins, which have been shown to have mood-enhancing properties.
Addiction[edit]
RB-101 has been researched for its potential use in the treatment of addiction. This is due to its ability to increase the concentration of enkephalins, which have been shown to reduce the rewarding effects of addictive substances.
